NCT05909826View on ClinicalTrials.gov

Carfilzomib, Oral Cyclophosphamide, and Dexamethasone for RRMM

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

July 1, 2023

Primary Completion Date

June 30, 2027

Study Completion Date

June 30, 2027

Conditions
Multiple Myeloma in RelapseMultiple Myeloma, Refractory
Interventions
DRUG

Carfilzomib

70 mg/m2 IV days 1, 8 and 15, every 4 weeks

DRUG

Cyclophosphamide

50 mg PO days 1 to 21, every 4 weeks

DRUG

Dexamethasone

40mg PO or IV days 1, 8, 15, and 22, every 4 weeks

All Listed Sponsors
lead

Dong-A University Hospital

OTHER